Literature DB >> 18819039

Hyperamylasaemia and/or hyperlipasaemia: incidence and underlying causes in hospitalized patients with non-pancreatic diseases.

Paul Georg Lankisch1, Christian Doobe, Thorsten Finger, Heiko Lübbers, Reiner Mahlke, Gisbert Brinkmann, Günter Klöppel, Patrick Maisonneuve, Albert B Lowenfels.   

Abstract

OBJECTIVE: There are no recommendations on how to proceed in patients with increased pancreatic enzyme activities but non-pancreatic diseases. The objective of this study was to investigate prospectively in a general medical hospital the incidence, causes and clinical impact of hyperamylasaemia and/or hyperlipasaemia in these patients.
MATERIAL AND METHODS: During a 4-month period in 2004, amylase and lipase activities were measured in all patients (n, 1765) admitted to the Department of Internal Medicine of the Municipal Clinic of Lüneburg, Germany. Patients with increased enzyme activities underwent abdominal ultrasonography and, if inconclusive, other imaging procedures.
RESULTS: Amylase and/or lipase activities were increased in 140 (8%) patients with non-pancreatic diseases: amylase in 29 cases (21%) and 1 case (1%)<3 and>3 times the upper limit of normal, respectively, lipase in 120 cases (86%) and 6 cases (4%)<3 and>3 times, respectively. In 53 (38%) patients no further imaging studies could be performed. In the remaining 87 patients amylase was increased in 18 patients (21%) and lipase in 3 patients (3%). The pancreas was normal on imaging procedures in 77 (89%) patients and abnormal in 10 (11%) (chronic pancreatitis: 4, small cystic lesions: 6). The cystic lesions were mostly located in the pancreas head, probably corresponding to branch-duct intraductal papillary mucinous neoplasm.
CONCLUSIONS: Increased pancreatic enzyme activities occur in 8% of hospitalized patients with non-pancreatic diseases, but pancreatic abnormalities will be found in only a few (11%), which are unlikely to need further investigation or therapy. Therefore, routine analysis of amylase or lipase activities in patients with non-pancreatic diseases is not indicated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18819039     DOI: 10.1080/00365520802400891

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  3 in total

1.  Sensitivity of Biochemical and Imaging Findings for the Diagnosis of Acute Pancreatitis in Children.

Authors:  Sarah H Orkin; Andrew T Trout; Lin Fei; Tom K Lin; Jaimie D Nathan; Tyler Thompson; David S Vitale; Maisam Abu-El-Haija
Journal:  J Pediatr       Date:  2019-08-06       Impact factor: 4.406

Review 2.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

Authors:  Juris J Meier
Journal:  Nat Rev Endocrinol       Date:  2012-09-04       Impact factor: 43.330

3.  Overlapping presence of macroamylasemia and hyperamylasemia in acute pancreatitis.

Authors:  Sun Young Cho; Anbok Lee; Hee Joo Lee; Jin-Tae Suh
Journal:  Korean J Lab Med       Date:  2011-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.